Related Experiment Video
Updated: Aug 6, 2026
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
Safety profile of small interfering RNA therapeutics: a systematic review and meta-analysis of randomized controlled
Cheewon Ahn1, Hyunsuk Jeong1, Hyeon Woo Yim1
1Department of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Objectives:
Small interfering RNAs (siRNAs) represent a promising therapeutic platform addressing unmet clinical needs. Recent advances have improved siRNA design, stability, specificity, and delivery; however, translating preclinical findings into clinical practice remains challenging due to the lack of standardized safety evaluation frameworks. This study conducted a systematic review and meta-analysis of placebo-controlled randomized clinical trials (RCTs) to quantitatively assess the safety of siRNA therapeutics and evaluate the adequacy of current preclinical safety assessments.
Methods:
PubMed, Embase, and Cochrane databases were searched from inception to July 2025. Two reviewers independently performed study selection and data extraction according to predefined criteria. Safety outcomes included death, serious adverse events (SAEs), severe adverse events, and adverse events (AEs) leading to treatment discontinuation. Pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated using R packages meta and metafor. Methodological quality for AE assessment was evaluated using the McHarm scale. The protocol was registered with PROSPERO (CRD420251120555).
Results:
Of 5,527 records screened, 57 studies (53 reports) evaluating 28 siRNA agents were included. Compared with controls, siRNA treatment did not increase the risk of death (RR 0.77, 95% CI 0.62-0.95) and severe AEs (RR 0.85, 95% CI 0.76-0.95), with no statistical heterogeneity (I2 = 0%). Risks of SAEs (RR 0.94, 95% CI 0.88-1.00) and treatment discontinuation (RR 0.86, 95% CI 0.66-1.13) were not increased.
Conclusion:
Chemical and delivery advancements have effectively enhanced siRNA safety. Nevertheless, ongoing vigilance and comprehensive safety monitoring during early clinical phases remain essential to identify unforeseen toxicities.
Systematic Review Registration:
Identifier CRD420251120555.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:15Experimental RNAi
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:30Small interfering RNAs (siRNA)
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
01:30Inhibitors of Viral Protein Synthesis